Johnson & Johnson (Janssen Biotech Inc.) / Genmab A/S
2012 · Licensing/Option · $3.0B · Complete
Announcement Sentiment
92
Strongly positive
Outcome Score
77
Worked — the deal delivered on its rationale.
Janssen licensed Genmab's DuoBody bispecific antibody platform, leading to development of teclistamab (Tecvayli) and other bispecific programs in oncology.